View More Recent Stories
-
Scott+Scott Attorneys at Law LLP Reminds Investors a Securities Action Has Been Filed Against Zynex, Inc. (ZYXI)
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZYXI
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZYXI
-
Scott+Scott Attorneys at Law LLP Alerts Investors an Action Has Been Filed Against Zynex, Inc. (ZYXI)
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZYXI
-
ZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation IntoZynex, Inc. (ZYXI)
-
Zynex Inc. (ZYXI) PT Lowered to $15 at H.C. Wainwright
-
RBC Capital Downgrades Zynex Inc. (ZYXI) to Sector Perform
-
Zynex, Inc. (ZYXI) Misses Q4 EPS by 12c, provides guidance
-
Zynex, Inc. (ZYXI) Announces Partnership To Conduct Business with Veterans Affairs Medical Centers
-
H.C. Wainwright Reiterates Buy Rating on Zynex Inc. (ZYXI)
-
Zynex (ZYXI) Announces Completion of Its Laser Pulse Oximetry Trial
-
Zynex Inc. (ZYXI) PT Raised to $17 at H.C. Wainwright
-
Zynex, Inc. (ZYXI) Tops Q3 EPS by 1c, provides guidance
-
H.C. Wainwright Reiterates Buy Rating on Zynex Inc. (ZYXI)
-
Zynex, Inc. (ZYXI) Receives FDA Clearance for New Pain Management Device
-
Zynex Inc. (ZYXI) PT Lowered to $16 at H.C. Wainwright
-
Zynex, Inc. (ZYXI) Misses Q2 EPS by 4c, Misses on Revenue; Offers FY24 Guidance
-
RBC Capital Reiterates Outperform Rating on Zynex Inc. (ZYXI)
